We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Panel Tests for Hundreds of Diseases Simultaneously

By LabMedica International staff writers
Posted on 16 Dec 2013
Image: The HiSeq 2000 sequencing system (Photo courtesy of Illumina).
Image: The HiSeq 2000 sequencing system (Photo courtesy of Illumina).
A new genetic sequencing test moves beyond assaying for one disease at a time, making it possible to identify more than 750 diseases triggered by mutations in children concomitantly and deliver results within six to eight weeks.

Currently, most genetic tests for childhood diseases are conducted one at a time, and this trial-and-error process consumes valuable time for clinicians in the search for the most effective treatment options for their patients and for families and the healthcare system, the prolonged hunt means higher costs.

Scientists at Children's Mercy Hospital (Kansas City, MO, USA) developed a screening panel, called the Targeted Gene Sequencing and Custom Analysis (TaGSCAN) that covers the 514 genetic regions that code for pediatric conditions with possible hereditary or elusive diagnoses. TaGSCAN is a hybrid of hypothesis-based and non-hypothesis-based testing. In a study involving 107 patients with neurodevelopmental disorders, 40 of these patients received new diagnoses as a result of the test. There were 10 cases where diagnosis was directly attributed to starting new treatments, discontinuing unnecessary medications or avoiding invasive procedures.

One advantage of the new test is that it can be ordered routinely. It has been used in over 180 patients at Children's Mercy since it was introduced in January 2013. The test looks at the genetic history of the patient's family, tests large numbers of genes, and combines the data with bioinformatic analysis. The test is highly sensitive, detecting approximately 95% of known genetic mutations in more than 750 diseases. Most of the genes on the panel are autosomal recessive, with few exceptions. The panel is rich in genes for neurodevelopmental, metabolic, nuclear mitochondrial, intellectual disability, and immunodeficiency conditions.

Stephen Kingsmore, MB ChB, DSc, director of the center for Pediatric Genomic Medicine at Children's Mercy, said, “There are about 7,000 diseases caused by single-gene mutations, about half of which have identified genetic causes. Genetic testing in critically ill babies might be able to identify the cause, but prior to development of this new approach, gene sequencing took too long, cost too much, and the findings were too complicated for practical use. This new diagnostic system currently includes signs and symptoms for 595 single-gene diseases for which the causes are known.” The study was presented at the 63rd Annual Meeting of the American Society Genomics (ASHG) held October 22–26, 2013, in Boston (MA, USA).

Related Links:

Children's Mercy Hospital


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automated MALDI-TOF MS System
EXS 3000

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more